149 related articles for article (PubMed ID: 29676875)
21. Clinical pharmacokinetics and pharmacodynamics of insulin aspart.
Lindholm A; Jacobsen LV
Clin Pharmacokinet; 2001; 40(9):641-59. PubMed ID: 11605714
[TBL] [Abstract][Full Text] [Related]
22. Role of ultrafast-acting insulin analogues in the management of diabetes.
Kruger DF; Novak LM
J Am Assoc Nurse Pract; 2019 Sep; 31(9):537-548. PubMed ID: 31385938
[TBL] [Abstract][Full Text] [Related]
23. Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide.
Kildegaard J; Buckley ST; Nielsen RH; Povlsen GK; Seested T; Ribel U; Olsen HB; Ludvigsen S; Jeppesen CB; Refsgaard HHF; Bendtsen KM; Kristensen NR; Hostrup S; Sturis J
Pharm Res; 2019 Feb; 36(3):49. PubMed ID: 30746556
[TBL] [Abstract][Full Text] [Related]
24. Performance of Fast-Acting Aspart Insulin as Compared to Aspart Insulin in Insulin Pump for Managing Type 1 Diabetes Mellitus: A Meta-Analysis.
Dutta D; Mohindra R; Mahajan K; Sharma M
Diabetes Metab J; 2023 Jan; 47(1):72-81. PubMed ID: 35746893
[TBL] [Abstract][Full Text] [Related]
25. CopenFast trial: Faster-acting insulin Fiasp versus insulin NovoRapid in the treatment of women with type 1 or type 2 diabetes during pregnancy and lactation - a randomised controlled trial.
Nørgaard SK; Mathiesen ER; Nørgaard K; Clausen TD; Damm P; Ringholm L
BMJ Open; 2021 Apr; 11(4):e045650. PubMed ID: 33837106
[TBL] [Abstract][Full Text] [Related]
26. Effective Overall Glycaemic Control with Fast-Acting Insulin Aspart Across Patients with Different Baseline Characteristics: A Post Hoc Analysis of the Onset 9 Trial.
Lane W; Favaro E; Jódar E; Kelkar P; Oviedo A; Sivarathinasami R; Senior PA; Sesti G; Franek E
Diabetes Ther; 2022 Apr; 13(4):761-774. PubMed ID: 35290624
[TBL] [Abstract][Full Text] [Related]
27. A comparison of pharmacokinetics and pharmacodynamics of insulin aspart, biphasic insulin aspart 70, biphasic insulin aspart 50, and human insulin: a randomized, quadruple crossover study.
Ma Z; Parkner T; Frystyk J; Laursen T; Lauritzen T; Christiansen JS
Diabetes Technol Ther; 2012 Jul; 14(7):589-95. PubMed ID: 22519735
[TBL] [Abstract][Full Text] [Related]
28. The impact of "faster aspart" on blood glucose control in children and adolescents with type 1 diabetes treated using a sensor-augmented insulin pump.
González de Buitrago Amigo J; González García A; Díaz Fernández P; Fernández Llamas M; Tejado Bravo ML; de Nicolás Jiménez JM; Ferrer Lozano M
An Pediatr (Engl Ed); 2021 Nov; 95(5):321-329. PubMed ID: 34645579
[TBL] [Abstract][Full Text] [Related]
29. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences.
Home PD
Diabetes Obes Metab; 2012 Sep; 14(9):780-8. PubMed ID: 22321739
[TBL] [Abstract][Full Text] [Related]
30. What is the value of faster acting prandial insulin? Focus on ultra rapid lispro.
Heise T; Piras de Oliveira C; Juneja R; Ribeiro A; Chigutsa F; Blevins T
Diabetes Obes Metab; 2022 Sep; 24(9):1689-1701. PubMed ID: 35593434
[TBL] [Abstract][Full Text] [Related]
31. Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when used with MiniMed
Grosman B; Wu D; Parikh N; Roy A; Voskanyan G; Kurtz N; Sturis J; Cohen O; Ekelund M; Vigersky R
Comput Methods Programs Biomed; 2021 Jun; 205():106087. PubMed ID: 33873075
[TBL] [Abstract][Full Text] [Related]
32. The association between anti-insulin aspart antibodies and the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in children and adolescents with type 1 diabetes.
Biester T; von dem Berge T; Bendtsen LQ; Bendtsen MD; Rathor N; Danne T; Haahr H
Pediatr Diabetes; 2020 Aug; 21(5):781-790. PubMed ID: 32306477
[TBL] [Abstract][Full Text] [Related]
33. Can Faster Aspart Be Used to Optimize Glycemic Control With Insulin Pump Therapy? From Expectations to Lessons Learned After a Year of Use in the United States.
Aleppo G; Bode B; Carlson AL
Clin Diabetes; 2022; 40(4):413-424. PubMed ID: 36381308
[TBL] [Abstract][Full Text] [Related]
34. Insulin aspart.
Simpson KL; Spencer CM
Drugs; 1999 May; 57(5):759-65; discussion 766-7. PubMed ID: 10353301
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions.
Hövelmann U; Heise T; Nosek L; Sassenfeld B; Thomsen KMD; Haahr H
Clin Drug Investig; 2017 May; 37(5):503-509. PubMed ID: 28185141
[TBL] [Abstract][Full Text] [Related]
36. Comparable Glucose Control with Fast-Acting Insulin Aspart Versus Insulin Aspart Using a Second-Generation Hybrid Closed-Loop System During Exercise.
Morrison D; Zaharieva DP; Lee MH; Paldus B; Vogrin S; Grosman B; Roy A; Kurtz N; O'Neal DN
Diabetes Technol Ther; 2022 Feb; 24(2):93-101. PubMed ID: 34524022
[No Abstract] [Full Text] [Related]
37. Clinical use of the co-formulation of insulin degludec and insulin aspart.
Kumar A; Awata T; Bain SC; Ceriello A; Fulcher GR; Unnikrishnan AG; Arechavaleta R; Gonzalez-Gálvez G; Hirose T; Home PD; Kaku K; Litwak L; Madsbad S; Pinget M; Mehta R; Mithal A; Tambascia M; Tibaldi J; Christiansen JS
Int J Clin Pract; 2016 Aug; 70(8):657-67. PubMed ID: 27384031
[TBL] [Abstract][Full Text] [Related]
38. [The comparison of insulin aspart and human soluble insulin used in insulin pump therapy in newly diagnosed type 2 diabetic patients].
Li YB; Liu J; Liao ZH; Liao Y; Deng WP; Weng JP
Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(35):2472-6. PubMed ID: 16321271
[TBL] [Abstract][Full Text] [Related]
39. Effects of mealtime insulin aspart and bedtime neutral protamine Hagedorn insulin on postprandial coagulation and fibrinolysis in patients with type 2 diabetes.
Bladbjerg EM; Henriksen JE; Akram S; Gram J
Diabetes Obes Metab; 2012 May; 14(5):447-53. PubMed ID: 22151836
[TBL] [Abstract][Full Text] [Related]
40. [Biphasic insulin aspart (NovoMix 50)].
Radermecker RP; Scheen AJ
Rev Med Liege; 2008 Nov; 63(11):688-92. PubMed ID: 19112996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
